Ubavitinib

AZD3229 is a potent pan-KIT mutant inhibitor for the treatment of gastrointestinal stromal tumors. AZD3229 inhibits c-KIT with an IC50 value of 223.3 nM[1][2].

Product Specifications

CAS Number

[2248003-60-1]

Product Name Alternative

AZD3229

UNSPSC

12352005

Target

C-Kit

Type

Reference compound

Related Pathways

Protein Tyrosine Kinase/RTK

Applications

Cancer-Kinase/protease

Field of Research

Cancer

Assay Protocol

https://www.medchemexpress.com/AZD3229.html

Purity

99.69

Solubility

DMSO : 40 mg/mL (ultrasonic)

Smiles

COCCOC1=CC(F)=C2C(N=CN=C2NC3=CC=C(NC(CN4C=C(C(C)C)N=N4)=O)C=C3)=C1

Molecular Formula

C24H26FN7O3

Molecular Weight

479.51

References & Citations

[1]Kettle JG, et al. Discovery of N- (4-{[5-Fluoro-7- (2-methoxyethoxy) quinazolin-4-yl]amino} phenyl) -2-[4- (propan-2-yl) -1 H-1,2,3-triazol-1-yl]acetamide (AZD3229), a Potent Pan-KIT Mutant Inhibitor for the Treatment of Gastrointestinal Stromal Tumors. J Med Chem. 2018 Oct 11;61 (19) :8797-8810.|[2]Ryu H, et.al. Antitumor Activity of a Novel Tyrosine Kinase Inhibitor AIU2001 Due to Abrogation of the DNA Damage Repair in Non-Small Cell Lung Cancer Cells. Int J Mol Sci. 2019 Sep 24;20 (19) :4728.